NYSEAMERICAN:LCTX - Lineage Cell Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.60
  • Forecasted Upside: 112.93 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.63
▼ -0.03 (-1.13%)

This chart shows the closing price for LCTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lineage Cell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LCTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LCTX

Analyst Price Target is $5.60
▲ +112.93% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lineage Cell Therapeutics in the last 3 months. The average price target is $5.60, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 112.93% upside from the last price of $2.63.

This chart shows the closing price for LCTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Lineage Cell Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/7/2021Chardan CapitalReiterated RatingBuy$4.00
3/30/2021Cantor FitzgeraldInitiated CoverageOverweight$6.00
3/12/2021Maxim GroupReiterated RatingBuy$5.00
2/24/2021HC WainwrightReiterated RatingBuy$7.00
10/12/2020Dawson JamesReiterated RatingBuy$6.00
9/17/2020Noble FinancialInitiated CoverageOutperform
9/2/2020HC WainwrightReiterated RatingBuy
8/7/2020Maxim GroupInitiated CoverageBuy$3.00
6/26/2020Maxim GroupInitiated CoverageBuy$3.00
6/10/2020HC WainwrightReiterated RatingBuy
6/2/2020Maxim GroupReiterated RatingBuy$3.00
5/12/2020Chardan CapitalReiterated RatingBuy
5/9/2020Maxim GroupInitiated CoverageBuy$3.00
5/5/2020HC WainwrightReiterated RatingBuy$4.00
3/13/2020HC WainwrightReiterated RatingBuy
2/10/2020HC WainwrightReiterated RatingBuy$4.00
1/3/2020HC WainwrightReiterated RatingBuy$4.00
11/13/2019HC WainwrightReiterated RatingBuy$4.00
10/15/2019Maxim GroupSet Price TargetBuy$3.00
8/22/2019Chardan CapitalReiterated RatingBuy
8/9/2019Maxim GroupSet Price TargetBuy$3.00
(Data available from 7/26/2016 forward)
Lineage Cell Therapeutics logo
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $2.63
Low: $2.62
High: $2.69

50 Day Range

MA: $1.69
Low: $1.43
High: $1.93

52 Week Range

Now: $2.63
Low: $0.79
High: $3.13

Volume

24,725 shs

Average Volume

1,609,371 shs

Market Capitalization

$426.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Lineage Cell Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Lineage Cell Therapeutics in the last year: Cantor Fitzgerald, Chardan Capital, Dawson James, HC Wainwright, Maxim Group, Noble Financial, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for LCTX.

What is the current price target for Lineage Cell Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Lineage Cell Therapeutics in the last year. Their average twelve-month price target is $5.60, suggesting a possible upside of 112.9%. HC Wainwright has the highest price target set, predicting LCTX will reach $7.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $4.00 for Lineage Cell Therapeutics in the next year.
View the latest price targets for LCTX.

What is the current consensus analyst rating for Lineage Cell Therapeutics?

Lineage Cell Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LCTX will outperform the market and that investors should add to their positions of Lineage Cell Therapeutics.
View the latest ratings for LCTX.

What other companies compete with Lineage Cell Therapeutics?

How do I contact Lineage Cell Therapeutics' investor relations team?

Lineage Cell Therapeutics' physical mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company's listed phone number is 510-871-4188 and its investor relations email address is [email protected] The official website for Lineage Cell Therapeutics is www.lineagecell.com.